- Adjuvant therapy was associated with extended survival in patients with stage IA pancreatic ductal adenocarcinoma (PDAC) with tumors 1-2 cm in diameter, but not in patients with tumors
Why this matters
- The study is the first to show that adjuvant therapy does not improve survival in patients with tumors this small.
- Previous studies suggested adjuvant therapy is broadly effective, but patients with stage I disease were underrepresented in the study populations.
- Retrospective analysis of 2004-2013 data from the National Cancer Data Base (n=1589) for patients diagnosed with T1 N0 resected PDAC.
- Funding: Emory University; National Cancer Institute.
- Overall, stage IA patients who received adjuvant therapy had a mean OS of 70.7 months compared with 46.9 months for those who did not receive adjuvant therapy (P=.0001).
- Patients with tumors 1-2 cm in size gained an OS benefit with adjuvant therapy (64.5 vs 30.8 months; P<.0001>
- Patients with subcentimeter tumors did not benefit: median OS was not reached in the adjuvant therapy group compared with 85.3 months with no additional treatment (P=.54).
- Retrospective design.